Browse studies

Find your next paid study

91 recruiting studies matching your filters

An Open-Label, Investigator-Initiated Study Evaluating the Use of Upadacitinib in Patients Hospitalized With Acute Severe Ulcerative Colitis

The goal of this clinical trial is to learn if the oral medication upadacitinib can safely and effectively treat acute severe ulcerative colitis (ASUC) in adul…

UC - Ulcerative Colitis

Estimated

~$10 – $5,625

University of California, San FranciscoNCT07502339

Phase 3

A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight

The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizum…

Ulcerative ColitisObesity or Overweight

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT06937086

Phase 1

A Phase Ib Study of Nivolumab in Patients With Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)

This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabo…

Autoimmune DiseaseCrohn DiseaseDermatomyositis+11 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT03816345

Phase 2

A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis

The main purpose of the study is to evaluate the effectiveness and safety of LY4268989 when given with mirikizumab compared to mirikizumab alone in adult parti…

Ulcerative Colitis

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07186101

Phase 2

A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to sever…

Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT07415044

Phase 3

A Master Protocol for a Phase 3, Multicenter, Open-label, Long-term Extension Study to Evaluate the Long-term Efficacy and Safety of Mirikizumab in Children and Adolescents With Moderate-to-severe Ulcerative Colitis or Crohn's Disease

The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (…

Ulcerative ColitisUlcerative Colitis ChronicInflammatory Bowel Diseases+1 more

Estimated

~$10 – $7,500

Eli Lilly and CompanyNCT04844606

Phase 4

An Open-Label, Phase 4, Single-Arm, Multicenter Study to Evaluate the Induction of Response and Remission of Vedolizumab Dual Targeted Therapy With Tofacitinib in Adult Patients With Moderately to Severely Active Ulcerative Colitis

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with tofacitinib in adults with moderate and se…

A Phase 2b, Double-Blind, Placebo-Controlled, Multicenter Proof of Concept Clinical Study to Evaluate the Efficacy and Safety of ATH-063 Induction Therapy in Patients With Biologic Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

The primary objective of this trial is to evaluate the clinical efficacy of ATH-063 in participants with biologic/advanced therapy relapsed/refractory moderate…

Ulcerative ColitisInflammatory Bowel DiseasesAutoimmune Diseases

Estimated

~$10 – $8,750

Athos Therapeutics IncNCT07513181

Phase 1

A Phase I, Multicenter, Open-Label, Single-Agent Study to Assess the Pharmacokinetics of Cytochrome P450 Substrates After Treatment With Afimkibart in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate the disease-drug-drug interaction (DDDI) potential of afimkibart (also known as RO7790121). This will be assessed by t…

Active Ulcerative Colitis

Estimated

~$10 – $7,500

Hoffmann-La RocheNCT07665723

Phase 3

A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 maintenance study to evaluate the efficacy and safety of duvakitug in participants …

Digital Mind Body Intervention Among Black and Hispanic Patients Living With Inflammatory Bowel Disease

The bidirectional effects between psychological distress and inflammatory bowel disease (IBD) activity mean that not only does increased IBD activity trigger p…

Crohn's DiseaseUlcerative ColitisInflammatory Bowel Diseases

Estimated

~$10 – $6,250

Montefiore Medical CenterNCT06510296

Observational

Microbiome-targeted Diet Therapy in Ulcerative Colitis

The central objective of this proposal is to test a novel diet capable of meeting the elevated protein requirements in ulcerative colitis (UC), while simultane…

Ulcerative Colitis

Estimated

~$10 – $6,250

University of MinnesotaNCT07520461